For HIV-positive people who develop non-Hodgkin’s lymphoma (NHL)—a cancer that is more common among people living with HIV than among negative people—including the drug Rituxan (rituximab) with the standard chemotherapy treatment significantly increases their chances of survival. Although Rituxan works by suppressing the immune system, adding the drug to standard chemo didn’t increase the risk of fatal opportunistic infections, even among people with CD4 counts hovering near 200.